首页> 外文期刊>European journal of human genetics: EJHG >A y(+)LAT-1 mutant protein interferes with y(+)LAT-2 activity: implications for the molecular pathogenesis of lysinuric protein intolerance.
【24h】

A y(+)LAT-1 mutant protein interferes with y(+)LAT-2 activity: implications for the molecular pathogenesis of lysinuric protein intolerance.

机译:y(+)LAT-1突变蛋白干扰y(+)LAT-2活性:对赖氨酸尿酸蛋白不耐受的分子发病机制的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Lysinuric protein intolerance (LPI) is an inherited aminoaciduria caused by defective cationic amino acid (CAA) transport at the basolateral membrane of epithelial cells in the intestine and kidney. The SLC7A7 gene, mutated in LPI, encodes the y(+)LAT-1 protein, which is the light subunit of the heterodimeric CAA transporter in which 4F2hc is the heavy chain subunit. Co-expression of 4F2hc and y(+)LAT-1 induces the y(+)L activity. This activity is also exerted by another complex composed of 4F2hc and y(+)LAT-2, the latter encoded by the SLC7A6 gene and more ubiquitously expressed than SLC7A7. On the basis of both the pattern of expression and the transport activity, y(+)LAT-2 might compensate for CAA transport when y(+)LAT-1 is defective. By expression in Xenopus laevis oocytes and mammalian cells, we functionally analysed two SLC7A7 mutants, E36del and F152L, respectively, the former displaying a partial dominant-negative effect. The results of the present study provide further insight into the molecular pathogenesis of LPI: a putative multiheteromeric structure of both [4F2hc/y(+)LAT-1] and [4F2hc/y(+)LAT-2], and the interference between y(+)LAT-1 and y(+)LAT-2 proteins. This interference can explain why the compensatory mechanism, that is, an increased expression of SLC7A6 as seen in lymphoblasts from LPI patients, may not be sufficient to restore the y(+)L system activity.
机译:赖氨酸尿酸蛋白不耐症(LPI)是一种遗传性氨基酸尿症,是由阳离子性氨基酸(CAA)在肠和肾上皮细胞的基底外侧膜上的运输缺陷所引起的。在LPI中突变的SLC7A7基因编码y(+)LAT-1蛋白,它是异二聚体CAA转运蛋白的轻亚基,其中4F2hc是重链亚基。 4F2hc和y(+)LAT-1的共表达诱导y(+)L活性。该活性还由另一种由4F2hc和y(+)LAT-2组成的复合物发挥作用,后者由SLC7A6基因编码,并且比SLC7A7更普遍表达。基于表达模式和转运活性,当y(+)LAT-1有缺陷时,y(+)LAT-2可能补偿CAA转运。通过在非洲爪蟾卵母细胞和哺乳动物细胞中的表达,我们在功能上分析了两个SLC7A7突变体E36del和F152L,前者表现出部分显性负效应。本研究的结果为LPI的分子发病机理提供了进一步的见解:[4F2hc / y(+)LAT-1]和[4F2hc / y(+)LAT-2]的推定多异体结构,以及y(+)LAT-1和y(+)LAT-2蛋白。这种干扰可以解释为什么补偿机制,即LLP患者淋巴母细胞中SLC7A6表达的增加,可能不足以恢复y(+)L系统活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号